Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis International IBD Genetics Consortium (IIBDGC), C Agliardi, L Alfredsson, ... Nature genetics 45 (11), 1353-1360, 2013 | 1346 | 2013 |
Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility International Multiple Sclerosis Genetics Consortium*†, ANZgene, ... Science 365 (6460), eaav7188, 2019 | 922 | 2019 |
Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20 Data analysis: Bahlo Melanie 2 Brown Matthew A 6 7 Browning Brian L 20 ... Nature genetics 41 (7), 824-828, 2009 | 542 | 2009 |
Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis JWL Brown, A Coles, D Horakova, E Havrdova, G Izquierdo, A Prat, ... Jama 321 (2), 175-187, 2019 | 485 | 2019 |
Defining secondary progressive multiple sclerosis J Lorscheider, K Buzzard, V Jokubaitis, T Spelman, E Havrdova, ... Brain 139 (9), 2395-2405, 2016 | 406 | 2016 |
Genome‐wide meta‐analysis identifies novel multiple sclerosis susceptibility loci NA Patsopoulos, ... Annals of neurology 70 (6), 897-912, 2011 | 363 | 2011 |
Geographical variations in sex ratio trends over time in multiple sclerosis M Trojano, G Lucchese, G Graziano, BV Taylor, S Simpson Jr, V Lepore, ... PloS one 7 (10), e48078, 2012 | 268 | 2012 |
Defining reliable disability outcomes in multiple sclerosis T Kalincik, G Cutter, T Spelman, V Jokubaitis, E Havrdova, D Horakova, ... Brain 138 (11), 3287-3298, 2015 | 211 | 2015 |
Predictors and dynamics of postpartum relapses in women with multiple sclerosis SE Hughes, T Spelman, OM Gray, C Boz, M Trojano, A Lugaresi, ... Multiple Sclerosis Journal 20 (6), 739-746, 2014 | 209 | 2014 |
Sex as a determinant of relapse incidence and progressive course of multiple sclerosis T Kalincik, V Vivek, V Jokubaitis, J Lechner-Scott, M Trojano, G Izquierdo, ... Brain 136 (12), 3609-3617, 2013 | 204 | 2013 |
Male sex is independently associated with faster disability accumulation in relapse-onset MS but not in primary progressive MS KA Ribbons, P McElduff, C Boz, M Trojano, G Izquierdo, P Duquette, ... PloS one 10 (6), e0122686, 2015 | 199 | 2015 |
Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis T Kalincik, D Horakova, T Spelman, V Jokubaitis, M Trojano, A Lugaresi, ... Annals of Neurology 77 (3), 425-435, 2015 | 189 | 2015 |
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study T Kalincik, JWL Brown, N Robertson, M Willis, N Scolding, CM Rice, ... The Lancet Neurology 16 (4), 271-281, 2017 | 172 | 2017 |
Fingolimod after natalizumab and the risk of short-term relapse VG Jokubaitis, V Li, T Kalincik, G Izquierdo, S Hodgkinson, R Alroughani, ... Neurology 82 (14), 1204-1211, 2014 | 157 | 2014 |
The multiple sclerosis whole blood mRNA transcriptome and genetic associations indicate dysregulation of specific T cell pathways in pathogenesis KS Gandhi, FC McKay, M Cox, C Riveros, N Armstrong, RN Heard, ... Human molecular genetics 19 (11), 2134-2143, 2010 | 154 | 2010 |
Multifocal motor neuropathy: the diagnostic spectrum and response to treatment M Slee, A Selvan, M Donaghy Neurology 69 (17), 1680-1687, 2007 | 148 | 2007 |
Towards personalized therapy for multiple sclerosis: prediction of individual treatment response T Kalincik, A Manouchehrinia, L Sobisek, V Jokubaitis, T Spelman, ... Brain 140 (9), 2426-2443, 2017 | 116 | 2017 |
Incidence and prevalence of NMOSD in Australia and New Zealand W Bukhari, KM Prain, P Waters, M Woodhall, MOG Cullen, L Clarke, ... Journal of Neurology, Neurosurgery & Psychiatry 88 (8), 632-638, 2017 | 116 | 2017 |
Steering Committees of Studies Evaluating IFNβ-1b and a CCR1-Antagonist. ANZgene Consortium. GeneMSA. International Multiple Sclerosis Genetics Consortium Genome-wide meta … NA Patsopoulos Ann Neurol 70 (6), 897-912, 2011 | 114 | 2011 |
Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study I Kister, T Spelman, R Alroughani, J Lechner-Scott, P Duquette, ... Journal of Neurology, Neurosurgery & Psychiatry 87 (10), 1133-1137, 2016 | 106 | 2016 |